ADVERTISEMENT

Protecting Neurons From The Effects Of Parkinson’s Disease

In our recent manuscript entitled Downregulation of SNCA expression by targeted editing of DNA-methylation: A potential strategy for precision therapy in PD, recently published in the journal Molecular Therapy journal (via Cell Press), we developed new therapeutic strategies targeting the regulation of SNCA expression. Elevated levels of SNCA have been implicated in the pathogenesis of Parkinson’s disease (PD). The gene encodes a protein called alpha-synuclein, which, when expressed in high levels, can be toxic as it tends to generate and be assembled in pathological aggregates in the brain of a Parkinson’s patient via formation of so-called Lewy bodies — the hallmark of this devastating neurological disease.

In our publication, we have developed a new approach to reduce the pathological levels of alpha-synuclein. The approach is based on epigenetic targeting that results in the modifications in gene functions without affecting gene composition per se. In an attempt to alleviate the pathological overexpression of alpha-synuclein, we employed highly innovative technology, called CRISPR/Cas9 which most recently has been repurposed to modulate gene expression in a precise fashion.

ADVERTISEMENT

We used an inactive form of Cas9 namely dCas9 which we fused with the catalytic (active) domain of an enzyme called DNA-methyltransferase 3A (DNMT3A). This enzyme is responsible for DNA methylation by means of adding methyl group that consists of one carbon and three hydrogen atoms — to a specific part of the SNCA gene (called intron 1). This modification instructs the DNA to create a closed “heterochromatin structure” that is generally inaccessible to transcription factors and RNA polymerase – the enzyme responsible for rewriting genetic information from DNA to RNA molecules. Lowering RNA synthesis results in the reduction of overall alpha-synuclein levels.

We constructed and applied the system to stem cell-derived dopamine-producing neurons — those primarily degenerated in Parkinson’s — from a patient with the SNCA gene triplication, which has been associated with increased production and aggregation of alpha-synuclein in Parkinson’s disease. To deliver dCas9-DNMT3A system to the cells, we used an optimized vehicle called a lentiviral vector. The vector has been evolved in Dr. Kantor’s laboratory to efficiently transport the therapeutic cargo inside the cells. By targeting DNA methylation at SNCA-intron 1, we were able to lower alpha-synuclein mRNA and protein levels. This reduction protected dopamine-producing neurons from characteristic disease-related changes. Specifically, Parkinson’s disease associates with dysfunction in mitochondria (the cells’ powerhouses that produce energy) which leads to pathological over-production of reactive oxygen species that damage all components of the cell, including proteins, lipids, and DNA- eventually leading to the cell death.

Our novel system protected neurons from this damage and other disease-related cellular-phenotypes characteristics of PD. The potential of CRISPR/dCas9 technology as a novel epigenetic-based therapeutic approach is huge and prospectively, our innovative platform that allows the regulation of gene expression programs to be fine-tuned would be highly attractive for developing ‘next generation drugs’ as prevention and/or disease-modifying interventions for PD, Alzheimer’s disease and other neurodegenerative diseases and pathologies associated with dysregulation of gene expression. In aiming to advance this system to the clinic, we now attempting to validate this therapeutic approach in vivo utilizing animal models of PD.

These findings are described in the article entitled Downregulation of SNCA expression by targeted editing of DNA-methylation: A potential strategy for precision therapy in PD, recently published in the journal Molecular TherapyThis work was conducted by Boris Kantor, Lidia Tagliafierro, Jeffrey Gu, Madison Elena Zamora, Ekaterina Ilich, Carole Grenier, Zhiqing Y. Huang, Susan Murphy, and Ornit Chiba-Falek from Duke University.

ADVERTISEMENT

Comments

READ THIS NEXT

Happy Faces And Friendly Choices: Analyzing Reactivity During Social Interactions

Pedagogic literature usually emphasizes the importance of being proactive rather than reactive. It is suggested that people who are reactive […]

Competition With Native Species Can Impact Reintroduction Success For The Endangered Pacific Pocket Mouse

As we enter into the Anthropocene, with the human impact on natural systems becoming ever greater, improving the success rates […]

Cerebral Blood Flow In Bipolar Disorder

Bipolar disorder is a psychiatric condition associated with alternating episodes of depression and mania or hypomania. Depression is a period […]

How Sulfur Makes Its Way Into The Soil Of Forested Ecosystems

The term “acid rain” may sound like an old legend to most people. This environmental issue, which once seriously threatened […]

Aggregation Induced Emission: Using New Luminescent Materials for Food Safety Monitoring

In 2016, the world shipped over USD 220 billion of meats and seafood. Naturally, ensuring the quality and safety of […]

Chronic Proton Pump Inhibitors May Increase Cancer Risk  

Proton pump inhibitors (PPIs): One in ten takes them, they are available without a prescription in many countries, so are […]

Moth-Eye Mimicking By Electrochemical Oxidation Of Aluminum

Nature has long inspired scientists around the world to engineer the materials of particular functional properties, such as anti-icing, non-wetting […]

Science Trends is a popular source of science news and education around the world. We cover everything from solar power cell technology to climate change to cancer research. We help hundreds of thousands of people every month learn about the world we live in and the latest scientific breakthroughs. Want to know more?